COVID-19 Update: Independent Conference Coverage of ECCMID 2023

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:

• Treatment in special populations
  • REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
  • Remdesivir and readmission for COVID-19 in immunocompromised patients
  • Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
• Management of patients with severe disease
  • RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
  • Real-world study of tocilizumab vs baricitinib for severe COVID-19
• Novel antivirals
  • Ensitrelvir
  • Bemnifosbuvir
•  Novel vaccines
  • NB2155
  • AZD2816/AZD1222
  • qNIV/CoV2373
  • GRT-R910
  • NVX-CoV2373 in people with HIV

Faculty:  
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland

Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  

Link to full program: 
bit.ly/3niXGJ6

Link to downloadable slides: 
bit.ly/3LUFejG